busulfan
busulfan: developed by 1 company · 28 clinical trials tracked · 1 FDA decision.
busulfan evidence translation
What we can confirm
1 FDA record · 28 tracked trials
What it means
What to watch
Prepared research question
How could busulfan → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 8 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) | Approved |
| NEXUS BIOPHARMA INC (NEXS) | Approved |
Clinical Trials (28)showing 10 most recent
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Primary endpoint: Determination of the maximum tolerated dose (MTD)
A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined With Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation Then Venetoclax Maintenance in Adult Patients With Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study
Primary endpoint: Event free survival (EFS)
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Primary endpoint: Incidence of grade 3 or higher adverse events (AEs)
A Prospective, Single-arm, Single-center, Open-label Clinical Study on the Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation for Elderly Patients With Hematologic Malignancies
Primary endpoint: 180-day non-recurrence mortality rate
Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Primary endpoint: Incidence of grade II-IV graft versus host disease (GVHD) requiring systemic immune suppression
Part B- Phase I/II, Non-Randomized, Single Site Study, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Primary endpoint: Safety
Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
Primary endpoint: Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Primary endpoint: Safety and adverse events (AEs)
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Primary endpoint: Safety and adverse events (AEs)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Primary endpoint: Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Frequently asked questions
Who is developing busulfan?
busulfan is being developed by NEXUS BIOPHARMA INC.
How many clinical trials involve busulfan?
BioSniper tracks 28 clinical trials involving busulfan.
What is busulfan's latest FDA decision?
The most recent tracked FDA decision for busulfan is Approval, dated January 14, 2019.